Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)

Cancer Research

Volumn 71, Issue 3, 2011, Pages 1009-1018

  Wild, Damian ^a,b   Frischknecht, Michael ^a   Zhang, Hanwen ^a   Morgenstern, Alfred ^c   Bruchertseifer, Frank ^c   Boisclair, Julie ^d   Provencher Bolliger, Anne ^d   Reubi, Jean Claude ^e   Maecke, Helmut R ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

^c JOINT RESEARCH CENTRE   (Italy)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMBA BI 213; ANTINEOPLASTIC AGENT; DOTA PEGYLATED 4 BOMBESIN BI 213; DOTA PEGYLATED 4 BOMBESIN LU 177; GASTRIN RELEASING PEPTIDE RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOPEPTIDE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSIMETRY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TUMOR LEVEL; DRUG UPTAKE; GLOMERULOPATHY; HUMAN; HUMAN CELL; INFARCTION; ISOTOPE LABELING; KIDNEY; KIDNEY INJURY; MAXIMUM TOLERATED DOSE; MOUSE; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PANCREAS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; TUMOR NECROSIS; TUMOR XENOGRAFT;

ALPHA PARTICLES; ANIMALS; BETA PARTICLES; BISMUTH; FEMALE; HUMANS; LUTETIUM; MALE; MICE; MICE, NUDE; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79551553871     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1186     Document Type: Article

References (49)

1. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632-42.
2. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291:1325-32.
3. Chatal J-F, Barbet J. Therapeutic use of radiolabeled antibodies: solid tumors. In: Ell PJ, Gambhir SS, editors. Nuclear medicine in clinical diagnosis and treatment. 3rd ed. London: Churchill Livingstone; 2004;p. 435-44.
4. Maecke HR, Mueller-Brand J. Receptor-targeted radiopeptide therapy. In: Ell PJ, Gambhir SS, editors. Nuclear medicine in clinical diagnosis and treatment. 3rd ed. London: Churchill Livingstone; 2004; p. 459-72.
5. 3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-30.
6. Davies AJ. Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. Oncogene 2007;26:3614-28.
7. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57.
8. Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994;35:1017-22.
9. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004;22:2522-31. (Pubitemid 41103739)
10. 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23:4591-601.
11. Hall EJ. Radiobiology for the radiologist. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000; p. 91-111.
12. 213Bi]anti- CD45 antibodies in leukemia cells. Cancer Res 2007;67:1950-8.
13. Brechbiel MW. Targeted alpha-therapy: past, present, future?Dalton Trans 2007;4918-28.
14. 211At-labeled monoclonal antibodies. Nucl Med Biol 2007;34:779-85.
15. 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. Cancer Res 1999;59:2635-43.
16. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002;100:1233-9. (Pubitemid 34864277)
17. Raja C, Graham P, Abbas Rizvi SM, Song E, Goldsmith H, Thompson J, et al. Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2007;6:846-52. (Pubitemid 351574972)
18. 225Ac as a source of alpha-particles in radioimmunotherapy. Nucl Med Commun 1993;14:121-5.
19. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994;271:58-65.
20. Jain RK. Delivery of molecular medicine to solid tumors. Science 1996;271:1079-80.
21. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003;44:610-7. (Pubitemid 40003748)
22. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989;63:1714-20.
23. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999;59:1152-9.
24. 125I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res 2002;8:1139-46.
25. Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC, et al. Synthesis and evaluation of bombesin derivatives on the basis of panbombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 2004;64:6707-15. (Pubitemid 39302601)
26. 99mTc: a preclinical study. J Med Chem 2005;48:100-10.
27. Maina T, Nock BA, Zhang H, Nikolopoulou A, Waser B, Reubi JC, et al. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J Nucl Med 2005;46:823-30.
28. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging 2003;30:1378-82.
29. 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006;47:1144-52.
30. Ananias HJ, de Jong IJ, Dierckx RA, van de Wiele C, Helfrich W, Elsinga PH. Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals. Curr Pharm Des 2008;14:3033-47.
31. Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007;34:1198-208.
32. Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem 2005;77:6288-91. (Pubitemid 39655916)
33. Zielinska B, Apostolidis C, Bruchertseifer F, Morgenstern A. An improved method for the production of Ac-225/Bi-213 from Th-229 for targeted alpha therapy. Sol Extr Ion Exch 2007;25:339.
34. Gotthardt M, van Eerd-Vismale J, Oyen WJ, de Jong M, Zhang H, Rolleman E, et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 2007;48:596-601.
35. 111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res 2007;13:3696-705.
36. Behr TM, Goldenberg DM. Improved prospects for cancer therapy with radiolabeled antibody fragments and peptides?J Nucl Med 1996;37:834-6.
37. Heimann M, Kasermann HP, Pfister R. Development of sublingual blood sampling in mice with assessment of clinical pathology parameters and comparison versus retrobular sampling. Vet Clin Path 2006;35:478.
38. Sharkey RM, Blumenthal RD, Behr TM, Wong GY, Haywood L, Forman D, et al. Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. Int J Cancer 1997;72:477-85.
39. 3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clin Cancer Res 2006;12:897-903.
40. 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res 2008;14:3555-61.
41. Miao Y, Hylarides M, Fisher DR, Shelton T, Moore H, Wester DW, et al. Melanoma therapy via peptide-targeted {alpha}-radiation. Clin Cancer Res 2005;11:5616-21.
42. Drecoll E, Gaertner FC, Miederer M, Blechert B, Vallon M, Muller JM, et al. Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS One 2009;4:e5715.
43. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, Bander NH. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate 2004;58:145-55.
44. Valentin J. Relative biological effectiveness (RBE), quality factor (Q), and radiation weighting factor (wr): ICRP Publication 92. Annals of the ICRP 2003;33:1-121.
45. 177Lu-AMBA. Eur J Nucl Med Mol Imaging 2007;34:95-100.
46. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000;60:6095-100.
47. Humm JL, Cobb LM. Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med 1990;31:75-83.
48. 213Bi for alpha-emitter targeting of metastatic breast cancer. Cancer Res 2010;70:6815-23.
49. Prise KM, O'Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer 2009;9:351-60.